News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,338 Results
Type
Article (14287)
Company Profile (281)
Press Release (254770)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79549)
Career Advice (153)
Deals (13234)
Drug Delivery (35)
Drug Development (50471)
Employer Resources (31)
FDA (5730)
Job Trends (5140)
News (144470)
Policy (10034)
Tag
Academia (916)
Accelerated approval (3)
Adcomms (13)
Allergies (52)
Alliances (21688)
ALS (69)
Alzheimer's disease (854)
Antibody-drug conjugate (ADC) (110)
Approvals (5757)
Artificial intelligence (134)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (61)
Brain cancer (20)
Breast cancer (165)
Cancer (1546)
Cardiovascular disease (122)
Career advice (134)
Career pathing (2)
CAR-T (127)
Cell therapy (349)
Cervical cancer (9)
Clinical research (41210)
Collaboration (569)
Compensation (286)
Complete response letters (13)
COVID-19 (1036)
CRISPR (48)
C-suite (173)
Cystic fibrosis (78)
Data (1654)
Denatured (11)
Depression (32)
Diabetes (146)
Diagnostics (1304)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (88)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (96)
Earnings (30290)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48882)
Executive appointments (479)
FDA (6517)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (526)
Gene editing (107)
Generative AI (10)
Gene therapy (277)
GLP-1 (375)
Government (1084)
Grass and pollen (2)
Guidances (75)
Healthcare (6596)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (100)
Indications (20)
Infectious disease (1103)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7289)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (215)
Leadership (3)
Legal (1388)
Liver cancer (34)
Lung cancer (212)
Lymphoma (107)
Machine learning (5)
Management (7)
Manufacturing (148)
MASH (65)
Medical device (2604)
Medtech (2605)
Mergers & acquisitions (6297)
Metabolic disorders (416)
Multiple sclerosis (55)
NASH (13)
Neurodegenerative disease (78)
Neuropsychiatric disorders (26)
Neuroscience (1291)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (23)
Obesity (201)
Opinion (103)
Ovarian cancer (67)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (126)
Partnered (8)
Patents (141)
Patient recruitment (85)
Peanut (35)
People (25696)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14565)
Phase II (19179)
Phase III (12102)
Pipeline (1007)
Policy (49)
Postmarket research (852)
Preclinical (6174)
Press Release (30)
Prostate cancer (64)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (303)
Real estate (1419)
Recruiting (12)
Regulatory (8683)
Reports (18)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (6)
RNA editing (8)
RSV (10)
Schizophrenia (64)
Series A (103)
Series B (71)
Service/supplier (1)
Sickle cell disease (43)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1977)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (219)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (74)
Last 7 days (600)
Last 30 days (2110)
Last 365 days (19338)
2025 (7514)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23356)
2019 (16223)
2018 (11739)
2017 (13745)
2016 (11839)
2015 (14350)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (44)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17365)
Australia (2948)
California (4201)
Canada (1199)
China (380)
Colorado (160)
Connecticut (157)
Delaware (112)
Europe (37393)
Florida (512)
Georgia (128)
Idaho (16)
Illinois (245)
India (10)
Indiana (94)
Iowa (3)
Japan (84)
Kansas (64)
Kentucky (5)
Louisiana (4)
Maine (11)
Maryland (503)
Massachusetts (3332)
Michigan (77)
Minnesota (156)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1024)
New Mexico (12)
New York (1114)
North Carolina (580)
North Dakota (6)
Northern California (1878)
Ohio (118)
Oklahoma (9)
Oregon (21)
Pennsylvania (785)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1604)
Tennessee (26)
Texas (487)
United States (14269)
Utah (56)
Virginia (87)
Washington D.C. (32)
Washington State (371)
Wisconsin (20)
269,338 Results for "lacerta therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Lacerta Therapeutics Expands Executive Leadership Team
Lacerta Therapeutics announces an expansion in the executive leadership team: Kenneth Warrington, Jr., PhD, co-founder of Lacerta, has joined as the company’s Chief Technology Officer, and Darin Falk, PhD, former Vice President of Gene Therapy Programs at Lacerta, will now serve as the company’s Chief Scientific Officer.
March 1, 2022
·
3 min read
Business
Concept Companies Leads Development Efforts on Second Phase for Lacerta Therapeutics in Alachua’s Progress District
Concept Companies, a national commercial real estate developer specializing in turnkey projects, announces the commencement of the design and construction of a new 11,961-square-foot laboratory facility for Lacerta Therapeutics, Inc., a gene therapy company.
May 27, 2022
·
3 min read
BioMidwest
Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement to Develop Novel AAV Capsids for CNS Disorders
Lacerta Therapeutics, a leader in the development of adeno-associated virus technologies for the treatment of central nervous system diseases, announced a new AAV capsid licensing and research collaboration agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company.
August 23, 2022
·
2 min read
BioMidwest
GrowFL Announces Lacerta Therapeutics as an Honoree: 11th Annual Florida Companies to Watch
Lacerta Therapeutics is pleased to be among the top 50 second-stage companies in Florida selected as an 11th Annual GrowFL Florida Companies to Watch honoree, a statewide competition that identifies companies expected to see significant growth over the next several years.
February 16, 2022
·
3 min read
Business
Lacerta Therapeutics Appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors
Lacerta Therapeutics, Inc. a gene therapy company dedicated to the discovery and development of AAV-based gene therapies, appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors.
November 24, 2021
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
Press Releases
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada
May 8, 2025
·
6 min read
Press Releases
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
April 17, 2025
·
13 min read
Press Releases
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
April 15, 2025
·
7 min read
1 of 26,934
Next
